SteadySharesSteadyShares
The market
MarketsDiscover
Follow the money
Smart MoneyPolitician TradesCrypto Desk
Yours
My WealthNews
Settings Sign in to save your work
Closed
SteadySharesMarketsDiscoverSmart MoneyMy WealthPoliticiansCryptoNews
/
DiscoverBMY
HealthcareNYSEUSD

Bristol-Myers Squibb

$0012345678900123456789.0012345678900123456789+8.2%
52w low (est.) $50.12$74.53 52w high (est.)
Peers
Market data
Market cap
$117.58B
52-week range
$42.52 – $62.89
Beta (vs market)
0.23
Sector
Healthcare
Valuation
P/E ratio
16.1x
DCF fair value
$79.61
Margin of safety
+31.6%
Forward P/E
9.3x
PEG ratio
1.49
Dividend yield
4.38%
Quality & efficiency
Moat score
71/100
Return on equity
38.7%
Profit margin
15.0%
Debt / equity
2.31
Growth & analysts
Revenue growth (YoY)
+2.6%
Analyst target
$63.00
Target upside
+4.1%
Analysts covering
24

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

Valuation

ValueGrowthProfitHealthIncome57QUALITY
Overall Rating
82
Strong Buy
Strong Buy
Moat Score71
DCF Intrinsic Value
$79.61+31.6% upside

Moat, DCF and rating computed by our valuation engine (ported from the original Python model).

Fundamentals

Market Cap
$117.58B
P/E Ratio
16.1
Dividend Yield
4.38%
Revenue Growth
+2.6%
Profit Margin
15.0%
ROE
38.7%
Debt / Equity
2.31
Beta
0.23
Dividend Aristocrats
vs Healthcare sector:P/E 16 vs 28 · cheaperMoat 71 vs 7Yield 4.38% vs 0.3%

Statistics

Similar Stocks · Healthcare

LLY73
$920.00+0.7%
AZN.L72
£105.20+0.6%
UNH71
$492.10+1.6%
JNJ70
$146.20-0.2%

Latest News · BMY